Silo Pharma reports promising preclinical results in treating severe stress-related disorders

Proactive - Interviews for investors

Silo Pharma CEO Eric Weisblum joined Steve Darling from Proactive to discuss the company’s positive findings from a preclinical study on its novel dual-target formulation designed to address major depressive disorder and severe stress-related conditions. Weisblum highlighted the promising potential of the treatment to deliver enhanced outcomes by combining two therapeutic approaches. The study revealed that this formulation, which simultaneously targets two key pathways linked to mood and stress regulation, demonstrated superior effectiveness in reducing stress-induced behaviors compared to treatments focusing on a single pathway. Animal models showed notable improvements in behavioral outcomes, suggesting the approach could be particularly effective in managing severe psychiatric challenges. Weisblum shared that the formulation is being explored as a potential intranasal preventative treatment for post-traumatic stress disorder (PTSD). The company is now preparing for an Investigational New Drug (IND) submission to progress to human clinical trials. “This study validates our innovative dual-target approach,” Weisblum stated. “By addressing two critical mechanisms simultaneously, we aim to set a new benchmark in care for patients struggling with debilitating stress-related conditions.” Silo Pharma’s advancements reflect its dedication to developing groundbreaking solutions for complex psychiatric disorders. The company is optimistic about transitioning its research into clinical development to meet the urgent need for improved mental health treatments. #proactiveinvestors #silopharmainc #nasdaq #silo #BiotechNews #SPC15 #PTSDTreatment #ChronicPain #Fibromyalgia #FDAApproval #EricWeisblum #PharmaUpdates #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews